Leveraging cutting-edge
scientific research and technology
Who we are
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders.
Our mission
We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
Our approach
By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based therapies.
GABA Therapeutics receives approval to begin phase I clinical trials
This week, GABA Therapeutics, a recent addition to the ATAI Life Sciences portfolio, announced
Reflections on the progress of psychedelic medicine
Since co-founding ATAI Life Sciences, I’ve been a firm believer in the power of psychedelic
ATAI’s Chief Scientific Officer addresses the future of psychiatric drug development at ISAD19
Last week, Srinivas Rao, Chief Scientific Officer of ATAI Life Sciences, spoke at the 10th
ATAI Life Sciences and Cyclica launch joint venture to revolutionize drug development for mental health disorders
Berlin and Toronto, November11, 2019 ATAI Life Sciences AG, a global biotech platform that envisions
GABA Therapeutics receives approval to begin phase I clinical trials
This week, GABA Therapeutics, a recent addition to the ATAI Life Sciences portfolio, announced
ATAI backs Neuronasal’s through-the-nose concussion treatment
Neuronasal is just the latest project for mental-health-focused ATAI. It has backed companies such as Compass Pathways, which is developing the psychedelic psilocybin, and Perception Neuroscience, which is working on a ketamine-like drug, both for the treatment of depression.
ATAI Life Sciences, Cyclica team up for mental health JV
Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new joint venture aimed at battling mental health.
The Power of Combining 5G and AI
Putting the two technologies together will change everything from drug making to brewing beer.
Can a Trip-Free Psychedelic Still Help People With Depression?
Psilocybin has shown promise for conditions like depression. Now, researchers are asking if the psychedelic experience is absolutely necessary to treat mental health.
ATAI backs Neuronasal’s through-the-nose concussion treatment
Neuronasal is just the latest project for mental-health-focused ATAI. It has backed companies such as Compass Pathways, which is developing the psychedelic psilocybin, and Perception Neuroscience, which is working on a ketamine-like drug, both for the treatment of depression.
Work with us
to improve the lives of millions of people
WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.
Join the ATAI #InsightNetwork
Sign up below to receive the latest news on ATAI and innovations in the biotech and mental healthcare space